Clinical Trial Lessons from V-Wave and Cardiac Dimensions
Dr. William Abraham, the new CMO at Cardiac Dimensions, previously led V-Wave's pivotal trial.
The V-Wave's U.S. pivotal trial, RELIEVE-HF, demonstrated the Ventura interatrial shunt's safety but did not meet its efficacy endpoint.
- The study included patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
- Results showed benefits for HFrEF patients but not HFpEF patients.
The trial's design meant it wasn't the end of the road for V-Wave's technology.
Author's summary: Clinical trials provide valuable lessons for heart failure treatments.
More News
- Canada's immigration system is lost in the bushes
- What's on the ballot in the first general election since Donald Trump became president
- Jets have reportedly made final decision on Garrett Wilson after Breece Hall’s trade request
- "Moore keeps redistricting push alive in Maryland amid national map fights" #ELB
- Half-billion-year-old parasite still threatens shellfish
- Mexican Authorities Suspect That Mayor Was Killed By The Jalisco Cartel: Report
- Pike man arrested for breaking into home, threatening woman - Mountain Top Media
- Reward offered for Dayton murder suspect who fled to Middletown
- All proceedings to be moved out of Pikeville federal courthouse - Mountain Top Media
- Vandalism: FCT NSCDC to prosecute offenders according to stringent laws - The Nation Newspaper